Zai Lab Limited (ZLAB)
ZLAB Stock Price Chart
Explore Zai Lab Limited interactive price chart. Choose custom timeframes to analyze ZLAB price movements and trends.
ZLAB Company Profile
Discover essential business fundamentals and corporate details for Zai Lab Limited (ZLAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Sept 2017
Employees
1.87k
Website
https://www.zailaboratory.comCEO
Ying Du
Description
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
ZLAB Financial Timeline
Browse a chronological timeline of Zai Lab Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.67, while revenue estimate is $104.01m.
Earnings released on 7 May 2026
EPS came in at -$0.46 surpassing the estimated -$0.53 by +12.57%, while revenue for the quarter reached $99.61m , missing expectations by -8.14%.
Earnings released on 26 Feb 2026
EPS came in at -$0.46 falling short of the estimated -$0.44 by -4.55%, while revenue for the quarter reached $127.60m , beating expectations by +4.45%.
Earnings released on 6 Nov 2025
EPS came in at -$0.33 falling short of the estimated -$0.28 by -17.86%, while revenue for the quarter reached $116.10m , missing expectations by -18.07%.
Earnings released on 7 Aug 2025
EPS came in at -$0.37 matching the estimated -$0.37, while revenue for the quarter reached $109.98m , missing expectations by -11.98%.
Earnings released on 8 May 2025
EPS came in at -$0.45 surpassing the estimated -$0.50 by +10.00%, while revenue for the quarter reached $106.49m , missing expectations by -5.41%.
Earnings released on 27 Feb 2025
EPS came in at -$0.80 falling short of the estimated -$0.61 by -31.15%, while revenue for the quarter reached $109.07m , missing expectations by -0.24%.
Earnings released on 12 Nov 2024
EPS came in at -$0.42 surpassing the estimated -$0.75 by +44.00%, while revenue for the quarter reached $102.27m , beating expectations by +0.02%.
Earnings released on 6 Aug 2024
EPS came in at -$0.82 falling short of the estimated -$0.66 by -24.24%, while revenue for the quarter reached $100.11m , beating expectations by +7.45%.
Earnings released on 8 May 2024
EPS came in at -$0.55 surpassing the estimated -$0.93 by +40.86%, while revenue for the quarter reached $87.15m , beating expectations by +15.83%.
Earnings released on 27 Feb 2024
EPS came in at -$0.98 falling short of the estimated -$0.87 by -12.64%, while revenue for the quarter reached $65.82m , missing expectations by -8.76%.
Earnings released on 7 Nov 2023
EPS came in at -$0.71 surpassing the estimated -$0.94 by +24.47%, while revenue for the quarter reached $69.23m , beating expectations by +4.24%.
Earnings released on 7 Aug 2023
EPS came in at -$1.25 falling short of the estimated -$0.79 by -58.15%, while revenue for the quarter reached $68.86m , missing expectations by -2.29%.
Earnings released on 9 May 2023
EPS came in at -$0.51 surpassing the estimated -$0.94 by +45.74%, while revenue for the quarter reached $62.80m , missing expectations by -3.57%.
Earnings released on 28 Feb 2023
EPS came in at -$0.65 surpassing the estimated -$1.04 by +37.50%, while revenue for the quarter reached $62.60m , missing expectations by -0.30%.
Earnings released on 9 Nov 2022
EPS came in at -$1.68 falling short of the estimated -$1.25 by -34.54%, while revenue for the quarter reached $57.54m , beating expectations by +7.06%.
Earnings released on 9 Aug 2022
EPS came in at -$1.44 falling short of the estimated -$1.08 by -33.87%, while revenue for the quarter reached $48.18m , beating expectations by +2.23%.
Earnings released on 10 May 2022
EPS came in at -$0.86 surpassing the estimated -$1.22 by +29.51%, while revenue for the quarter reached $46.72m , beating expectations by +4.82%.
Earnings released on 1 Mar 2022
EPS came in at -$2.24 falling short of the estimated -$1.33 by -67.94%, while revenue for the quarter reached $44.17m , missing expectations by -7.77%.
Earnings released on 9 Nov 2021
EPS came in at -$1.01 surpassing the estimated -$1.24 by +18.55%, while revenue for the quarter reached $43.10m , beating expectations by +32.79%.
Earnings released on 9 Aug 2021
EPS came in at -$1.76 falling short of the estimated -$1.55 by -13.55%, while revenue for the quarter reached $36.94m , beating expectations by +13.79%.
ZLAB Stock Performance
Access detailed ZLAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
